Literature DB >> 30362022

Diagnosis and Treatment of Myxoid Liposarcomas: Histology Matters.

Sarah Abaricia1, Angela C Hirbe2,3.   

Abstract

OPINION STATEMENT: Sarcomas are a heterogeneous group of rare malignancies that arise from mesenchymal cells and can occur anywhere in the body. Herein, the focus will be on one subtype of sarcoma that arises from adipocytic tissue, liposarcoma. Specifically, the review will focus on one type of liposarcoma, myxoid liposarcoma. Given the rarity of this tumor, it is imperative that these patients are treated at a sarcoma center, where a multidisciplinary approach incorporates all the modalities available including clinical trials. As the understanding of the biology of myxoid liposarcomas progresses, more targeted therapies are being developed that will lead to better tolerated treatments and improved survival for patients. In this review, we will be discussing the pathophysiology, clinical presentation, diagnostic workup, and available treatment options including surgery, radiation, chemotherapy, and clinical trials.

Entities:  

Keywords:  Myxoid liposarcoma; Pathology; Staging; Treatments

Mesh:

Substances:

Year:  2018        PMID: 30362022     DOI: 10.1007/s11864-018-0590-5

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  58 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

2.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Winette T A van der Graaf; Jean-Yves Blay; Sant P Chawla; Dong-Wan Kim; Binh Bui-Nguyen; Paolo G Casali; Patrick Schöffski; Massimo Aglietta; Arthur P Staddon; Yasuo Beppu; Axel Le Cesne; Hans Gelderblom; Ian R Judson; Nobuhito Araki; Monia Ouali; Sandrine Marreaud; Rachel Hodge; Mohammed R Dewji; Corneel Coens; George D Demetri; Christopher D Fletcher; Angelo Paolo Dei Tos; Peter Hohenberger
Journal:  Lancet       Date:  2012-05-16       Impact factor: 79.321

3.  Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.

Authors:  S Frustaci; F Gherlinzoni; A De Paoli; M Bonetti; A Azzarelli; A Comandone; P Olmi; A Buonadonna; G Pignatti; E Barbieri; G Apice; H Zmerly; D Serraino; P Picci
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

4.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

Authors:  G D Demetri; C D Fletcher; E Mueller; P Sarraf; R Naujoks; N Campbell; B M Spiegelman; S Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 5.  Liposarcoma: Multimodality Management and Future Targeted Therapies.

Authors:  Aimee M Crago; Mark A Dickson
Journal:  Surg Oncol Clin N Am       Date:  2016-07-30       Impact factor: 3.495

Review 6.  NY-ESO-1: a promising cancer testis antigen for sarcoma immunotherapy and diagnosis.

Authors:  Stephen M Smith; O Hans Iwenofu
Journal:  Chin Clin Oncol       Date:  2018-08

7.  Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group.

Authors:  R H Blum; J Edmonson; L Ryan; L Pelletier
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Evaluation of core needle biopsy as a substitute to open biopsy in the diagnosis of soft-tissue masses.

Authors:  I Ray-Coquard; D Ranchère-Vince; P Thiesse; H Ghesquières; P Biron; M-P Sunyach; M Rivoire; L Lancry; P Méeus; C Sebban; J-Y Blay
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

9.  Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.

Authors:  Claudia Forni; Mario Minuzzo; Emanuela Virdis; Elena Tamborini; Matteo Simone; Michele Tavecchio; Eugenio Erba; Federica Grosso; Alessandro Gronchi; Pierre Aman; Paolo Casali; Maurizio D'Incalci; Silvana Pilotti; Roberto Mantovani
Journal:  Mol Cancer Ther       Date:  2009-02-03       Impact factor: 6.261

Review 10.  Advances in the targeted therapy of liposarcoma.

Authors:  Zhonghai Guan; Xiongfei Yu; Haohao Wang; Haiyong Wang; Jing Zhang; Guangliang Li; Jiang Cao; Lisong Teng
Journal:  Onco Targets Ther       Date:  2015-01-05       Impact factor: 4.147

View more
  6 in total

1.  Primary High-Grade Myxoid Liposarcoma of the Extremities: Prognostic Factors and Metastatic Pattern.

Authors:  Gianmarco Tuzzato; Roberta Laranga; Federico Ostetto; Elisa Bubbico; Giulio Vara; Giuseppe Bianchi
Journal:  Cancers (Basel)       Date:  2022-05-27       Impact factor: 6.575

2.  Dendritic fibromyxolipoma: A case report.

Authors:  Hongyun Liu; Shumin Hei; Jigang Wang; Qiliang Zhang; Xinjuan Yu; Hua Chen
Journal:  Mol Clin Oncol       Date:  2020-11-12

3.  Texture analysis of magnetic resonance image to differentiate benign from malignant myxoid soft tissue tumors: A retrospective comparative study.

Authors:  Hyunsik Chang; Yusuhn Kang; Joong Mo Ahn; Eugene Lee; Joon Woo Lee; Heung Sik Kang
Journal:  PLoS One       Date:  2022-05-19       Impact factor: 3.240

4.  Diagnosis and Prognosis of Retroperitoneal Liposarcoma: A Single Asian Center Cohort of 57 Cases.

Authors:  Jianchun Xiao; Jianghao Liu; Minting Chen; Wei Liu; Xiaodong He
Journal:  J Oncol       Date:  2021-04-01       Impact factor: 4.375

5.  Solitary metastasis of myxoid liposarcoma from the thigh to intraperitoneum: a case report.

Authors:  Dong-Wook Kim; Ye Seob Jee
Journal:  World J Surg Oncol       Date:  2019-10-28       Impact factor: 2.754

6.  Different HSP90 Inhibitors Exert Divergent Effect on Myxoid Liposarcoma In Vitro and In Vivo.

Authors:  Christoffer Vannas; Lisa Andersson; Soheila Dolatabadi; Parmida Ranji; Malin Lindén; Emma Jonasson; Anders Ståhlberg; Henrik Fagman; Pierre Åman
Journal:  Biomedicines       Date:  2022-03-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.